Review your cardiovascular health history , including: Personal or family history of heart disease, arrhythmias, or sudden cardiac death Current blood pressure readings and any history of hypertension Symptoms such as palpitations, chest discomfort, or exercise intolerance Address appetite and weight concerns
Semaglutide, a GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management, works by activating brain receptors that regulate hunger and slowing gastric emptying
These symptoms can lead to reduced fluid intake and increased fluid losses, resulting in dehydration
Effects of the Sema + Cagrilintide Blend: Dual-Pathway Weight Loss: Investigated for the ability of combined GLP-1 and Amylin agonism to produce superior weight loss compared to monotherapy in rodent models
The good news is that this adjustment fatigue usually improves substantially within 3 to 4 weeks as your body adapts
By following these guidelines, you help maintain the integrity of semaglutide, ensuring it remains safe and effective for managing weight and blood sugar levels